Table 5.
Adverse effects of CoronaVac and the BNT162b2 booster 1.
| CoronaVac Group (n = 98) | BNT162b2 Group (n = 136) | p-Value | |
|---|---|---|---|
| No data | 10.2% (10/98) | 5.0% (7/136) | |
| No adverse effect | 74.5% (73/98) | 47.8% (65/136) | |
| Any adverse effect | 16.3% (16/98) | 50.7% (69/136) | <0.0001 |
| Fever | 4.5% (4/88) | 14.7% (19/129) | 0.0230 |
| Chills | 8.0% (7/88) | 7.0% (9/129) | 0.7967 |
| Injection site pain | 13.6% (12/88) | 39.5% (51/129) | <0.0001 |
| Fatigue | 6.8% (6/88) | 32.6% (42/129) | <0.0001 |
| Headache | 8.0% (7/88) | 14.0% (18/129) | 0.1995 |
| Muscle pain | 2.3% (2/88) | 34.9% (45/129) | <0.0001 |
| Diarrhoea | 2.3% (2/88) | 5.4% (7/129) | 0.3170 |
| Joint pain | 1.1% (1/88) | 14.7% (19/129) | 0.0005 |
| Skin rash | 2.3% (2/88) | 3.9% (5/129) | 0.7037 |
| Nausea/vomiting | 1.1% (1/88) | 2.3% (3/129) | 0.6483 |
| Tremor | 0 | 1.6% (2/129) | 0.5156 |
| Abdominal pain | 0 | 0.8% (1/129) | >0.99 |
| Urticaria | 0 | 1.6% (2/129) | 0.5156 |
| Enlarged lymph nodes | 0 | 1.6% (2/129) | 0.5156 |
| Sore throat | 0 | 3.9% (5/129) | 0.0821 |
| Nasal congestion | 0 | 5.4% (7/129) | 0.0432 |
| SAE 1 | 0 | 0 | >0.99 |
1 Serious Adverse Events were defined as vaccine-related undesired events, including disability, life-threatening conditions and death. All variables were tested using Fisher’s exact test.